Castillo GOI

Language: Spanish
References: 11
Page: 126-130
PDF size: 199.55 Kb.

ABSTRACT

Introduction: Neuromyelitis optica is a spectrum of autoimmune, inflammatory and demyelinating disorders of the central nervous system. It is recommended to institute immunosuppressive therapy after the first attack as a preventive relapse treatment. Objective: Analyze the clinical response to treatment measured by the annualized relapse rate and progression of disability with EDSS (Expanded Disability Status Scale), as well as clinical and demographic variables in subjects with NMO in the population of a reference hospital. Material and methods: An observational, retrospective, cross-sectional and descriptive study was conducted. Clinical and demographic variables were obtained from the clinical record; as well as the EDSS relapse index and disability score of patients who have received at least one year of immunosuppressant treatment as a preventive relapse treatment, from January 2010 to June 2017. Results: 60 patients were included. With an average age at diagnosis of 38.2 years, 88.3% female and 11.7% male. 13 patients received treatment with azathioprine, 19 with cyclophosphamide and 28 with rituximab. The azatioprina group presented a relapse index of 1.2 and EDSS of 4, in the cyclophosphamide of 1.6 with EDSS of 2.8, and in that of rituximab of 1 with EDSS of 2.8. Conclusions: Patients diagnosed with optic neuromyelitis with IgG + in immunosuppressive treatment preventive relapse, present significantly higher response to treatment with rituximab, demonstrated by a lower rate of relapse and lower EDSS.

REFERENCES

1. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85: 177-189.

2. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013; 10: 8.

3. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364: 2106-2112.

4. Wakayama Y. Aquaporin expression in normal and pathological skeletal muscles: A brief review with focus on AQP4. Journal of Biomedicine and Biotechnology. 2010, Article ID 731569, 9 pages.

5. Verkman AS, Ratelade J, Rossi A, Zhang H, Tradtrantip L. Aquaporin-4: orthogonal array assembly CNS functions, and role in neuromyelitis optica. Acta Pharmacologica Sin. 2011; 32: 702-710.

6. Ratelade J, Verkman AS. Neuromyelitis óptica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol. 2012; 44: 1519-1530.

7. Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation. 2008; 5: 2094.

8. Etemadifar M, Nasr Z, Khalili B, Taherioun M, Vosoughi R. Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis. Mult Scler Int. 2015; 2015: 174720.

9. Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017; 92 (4): 663-679.

10. Papadopoulos MC, Bennet JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol. 2014; 10: 493-506.

11. Etemadifar M, Salari M, Mirmosayyeb O et al. Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci. 2017; 22: 18.